FIELD: medicine, gene engineering, in particular production of new variants of gamma-interferon polypeptide having gamma-interferon activity.
SUBSTANCE: new polypeptide variants include S99T replacement in contrast with huIFNG amino acid sequence, may be shortened on C-end and are capable of enhancing utilization of natural N-glycosilation site in 97 place. Mutant forms of gamma-interferon containing threonine in 99 place may include from 1 to 10 modifications without losses polypeptide activity. Polypeptide is obtained by expression in host cells transformed with vector including nucleic acid encoding mutant IFNG. Conjugant of mutant with PEG is obtained by pegilation, wherein said conjugant has increased half-life time in serum and reduced immunogenicity. Obtained IFNG polypeptide is useful in pharmaceutical composition for treatment and prevention of interstitial pulmonary diseases.
EFFECT: mutant gamma-interferon with enhanced utilization of natural N-glycosilation site in 97 place in contrast with natural form of huIFNG.
43 cl, 3 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERFERON-GAMMA CONJUGATES | 2000 |
|
RU2268749C2 |
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
| G-CSG CONJUGATES | 2001 |
|
RU2290411C2 |
| VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa | 2004 |
|
RU2373282C2 |
| CONJUGATE OF ANTIBODY AND DRUG, COMPOSITIONS BASED ON SAID CONJUGATE AND METHODS OF PRODUCING SAID CONJUGATE | 2015 |
|
RU2728235C2 |
| HOMOGENEOUS ANTIBODY AND DRUG CONJUGATES PRODUCED BY ENZYMATIC METHODS | 2015 |
|
RU2796266C2 |
| SITE-SPECIFIC INSULIN CONJUGATE | 2014 |
|
RU2677800C2 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| NOVEL SOLUBLE POLYPEPTIDES CD83, COMPOSITIONS AND METHODS OF THEIR APPLICATION | 2009 |
|
RU2535340C2 |
| IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
